Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 12/20 | 1.00 |
| ▸ | RET | P07949 | 4/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.71 |
| ▸ | KDR | P35968 | 4/20 | 0.71 |
| ▸ | FLT1 | P17948 | 2/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.71 |
| ▸ | TLK2 | Q86UE8 | 6/20 | 0.68 |
| ▸ | JAK3 | P52333 | 5/20 | 0.68 |
| ▸ | SYK | P43405 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.68 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18054 | 1.00 | PDPK1 (1.00) | PDPK1RETFLT3ALKPDGFRB | |
| SCHEMBL5728607 | 0.89 | PDPK1 (0.80) | PDPK1RETFLT3ALKPDGFRB | |
| SCHEMBL5728610 | 0.89 | PDPK1 (0.80) | PDPK1RETFLT3ALKPDGFRB | |
| SCHEMBL6957030 | 0.86 | PDPK1 (0.76) | PDPK1RETFLT3ALKPDGFRB | |
| SCHEMBL6957025 | 0.86 | PDPK1 (0.76) | PDPK1RETFLT3ALKPDGFRB | |
| SCHEMBL396510 | 0.84 | PDPK1 (0.72) | PDPK1RETFLT3ALKPDGFRB | |
| SCHEMBL396509 | 0.84 | PDPK1 (0.72) | PDPK1RETFLT3ALKPDGFRB | |
| SCHEMBL5373346 | 0.83 | PDPK1 (0.71) | PDPK1RETFLT3ALKPDGFRB | |
| SCHEMBL5727973 | 0.83 | PDPK1 (1.00) | PDPK1RETFLT3ALKPDGFRB | |
| SCHEMBL5728408 | 0.83 | PDPK1 (0.76) | PDPK1RETFLT3ALKPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | claimed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | claimed |
| US-9567305-B2 | Quinoxaline compounds and derivatives | SOUTHERN METHODIST UNIVERSITY (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567305-B2 | Quinoxaline compounds and derivatives | SOUTHERN METHODIST UNIVERSITY (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2012025726-A1 | Novel Hybrid Compounds | UNIVERSITY OF GREENWICH (GB) | 2012-03-01 | — | — | WO | disclosed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | PDK3, PDK2, PDK4 | PDPK1 4/4885RET 1754/4885FLT3 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.